- What is claimed is:
- 1. A urinary tract disorder reference profile, comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 3, 6, 8-11, and 18.
- 2. The urinary tract disorder reference profile of claim 1, further comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 24-95.
- 3. A urinary tract disorder reference profile, comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 6 and 24-55.
- 4. A urinary tract disorder reference profile, comprising a pattern of one or more analytes or metabolites thereof, selected from the group consisting of UTD 3, 8-11, 18, 56-95.
- 5. A method of metabolomically predicting whether a subject is predisposed to developing a urinary tract disorder, comprising obtaining a urinary tract disorder reference profile from said subject and comparing the urinary tract disorder reference profile from said subject with a control urinary tract disorder reference profile, thereby predicting whether the subject is predisposed to having a urinary tract disorder.
- 6. The method of claim 5, wherein the urinary tract disorder is interstitial cystitis, prostatitis, kidney infection or inflammation, urethritis, prostrate hypertrophy, or urinary tract stones.
- 7. A method for identifying markers indicative of a urinary tract disorder in a subject comprising determining the levels of one or more analytes or metabolites thereof in a subject sample, wherein said analytes or metabolites are selected from the group consisting of UTD 3, 6, 8-11, and 18 and determining those analytes or metabolites that are present in a different concentration in the subject sample compared to a control sample, wherein the presence of said analytes or metabolite at a different concentration is indicative of a urinary tract disorder in said subject.
- 8. The method of claim 7, further comprising determining the concentration of one or more

- analytes or metabolites thereof selected from the group consisting of UTD 24-95.
- 9. The method of claim 7, wherein said subject sample is urine, prostatic fluid or urinary tract tissue.
- 10. The method of claim 7, wherein said control sample is derived from a subject known not to be suffering from or pre-disposed to developing a urinary tract disorder.
- 11. A method of diagnosing a urinary tract disorder (UTD) or a predisposition to developing a urinary tract disorder in a subject, comprising determining a level of a UTD-associated analyte in a subject derived sample, wherein an increase or decrease of said level compared to a normal control level indicates that said subject suffers from or is at risk of developing a urinary tract disorder.
- 12. The method of claim 11, wherein said UTD-associated analyte is selected from the group consisting of UTD 6 and 24-55, wherein an increase in said level compared to a normal control level indicates that said subject suffers from or is at risk of developing developing a urinary tract disorder.
- 13. The method of claim 12, wherein said increase is at least 1.1-fold greater than said normal control level.
- 14. The method of claim 11, wherein said analyte is selected from the group consisting of UTD 3, 8-11, 18 and 56-95, wherein a decrease in said level compared to a normal control level indicates that said subject suffers from or is at risk of developing developing a urinary tract disorder.
- 15. The method of claim 14, wherein said decrease is at least 10% less than said normal control level.
- 16. A method of assessing the efficacy of a treatment of a urinary tract disorder in a subject, comprising determining a level of a UTD-associated analyte in a subject sample derived after

treatment and comparing said level to a normal control level, thereby monitoring the treatment of the urinary tract disorder in said subject.

- 17. The method of claim 16, wherein a similarity of said level of said UTD-associated analyte in said subject sample compared to a said normal control level indicates that treatment is efficacious.
- 18. A method of determining the risk of developing a urinary tract disorder in a subject, comprising detecting an elevated concentration of an analyte or metabolite thereof selected from the group consisting of UTD 6 and 24-55 compared to the concentration of said analyte or metabolite in a control sample, wherein an elevated concentration of said analyte or metabolite indicates said subject is at risk of developing a urinary tract disorder.
- 19. A method of determining the risk of developing a urinary tract disorder in a subject, comprising detecting a decreased concentration of an analyte or metabolite thereof selected from the group consisting of UTD 3, 8-11, 18 and 56-95 compared to the concentration of said analyte or metabolite in a control sample, wherein a decreased concentration of said analyte or metabolite indicates said subject is at risk of developing a urinary tract disorder.
- 20. A method of identifying an agent that modulates the onset or progression of a urinary tract disorder in a subject, comprising:
 - i) contacting said subject with a candidate agent;

ar bei te ball ätte e

- ii) determining a test level of an analyte in a sample derived from said subject following said contacting;
- iii) comparing said test level with a reference level of said analyte, wherein an increase or decrease of said test level relative to said reference level indicates that said test agent modulates the onset or progression of a urinary tract disorder.
- 21. The method of claim 20, wherein said reference level is derived from a sample derived from said subject.
- 22. The method of claim 20, wherein said reference level is derived from a database.

- 23. The method of claim 22, wherein said database comprises test levels of an analyte in a sample derived from a database subject, wherein said database subject is not said test subject.
- 24. A kit comprising a detection reagent that identifies one or more analytes selected from the group consisting of UTD 3, 6, 8-11, 18, and 24-95.